New combo targets tough lymphoma subtypes in early trial

This study tests a new combination of drugs for people with a specific type of untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if the treatment can keep the cancer from coming back for at least two years. About 35 participants will receive six cycles of the drug combo, followed by a year of maintenance therapy. This is an early-phase trial, so the main focus is on safety and how well the treatment works.